Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 11/20 | 0.38 |
| ▸ | DRD4 | P21917 | 11/20 | 0.38 |
| ▸ | DRD3 | P35462 | 11/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3851943 | 0.91 | MEN1 (0.40) | CXCR3KMT2AALDH1A1HTTRAB9A | |
| Bromide SCHEMBL3843830 | 0.88 | ALDH1A1 (0.46) | LMNAKMT2AALDH1A1MAPTHTT | |
| Bromide SCHEMBL3848873 | 0.81 | ALDH1A1 (0.45) | LMNATSHRALDH1A1MAPTHPGD | |
| SCHEMBL11039344 | 0.78 | KMT2A (0.53) | CXCR3LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL7457718 | 0.78 | KMT2A (0.53) | CXCR3LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL7460876 | 0.78 | KMT2A (0.53) | CXCR3LMNATSHRKMT2AALDH1A1 | |
| Bromide SCHEMBL2532767 | 0.78 | RAB9A (0.51) | CXCR3LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL10950721 | 0.77 | KMT2A (0.54) | CXCR3LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL12220178 | 0.77 | GSK3B (0.52) | CXCR3LMNATSHRKMT2AALDH1A1 | |
| SCHEMBL2743413 | 0.74 | KMT2A (0.54) | CXCR3LMNATSHRKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198795-A1 | Substituted imidazoliums and methods of use therefor | SYNVISTA THERAPEUTICS, INC. | 2004-10-07 | — | — | US | claimed |
| EP-1213282-A1 | Substituted imidazolium salts and their use for the inhibition of protein ageing. | ALTEON Inc. (US) | 2002-06-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198795-A1 | Substituted imidazoliums and methods of use therefor | AGER, NOTUM, IDE | CXCR3 4735/4885LMNA 2384/4885TSHR 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.